SGLT2 Inhibitor Dose Equivalency for Normal eGFR
For a patient with normal eGFR switching from canagliflozin (Invokana) 300 mg, use empagliflozin (Jardiance) 25 mg or dapagliflozin (Farxiga) 10 mg daily.
Dosing Rationale
The FDA-approved maximum doses for SGLT2 inhibitors with normal kidney function are 1:
- Canagliflozin: 300 mg daily (when eGFR ≥60 mL/min/1.73 m²)
- Empagliflozin: 25 mg daily (no adjustment needed when eGFR ≥45 mL/min/1.73 m²)
- Dapagliflozin: 10 mg daily (standard dose across all eGFR ranges)
Since your patient is on the maximum dose of canagliflozin (300 mg), the equivalent therapeutic approach is to use the maximum approved doses of the alternative agents.
Key Differences Between Options
Empagliflozin (Jardiance) 25 mg
- Cardiovascular outcomes: Demonstrated 38% reduction in CV death in EMPA-REG OUTCOME trial 1
- All-cause mortality: 32% reduction (HR 0.68) 1
- Heart failure hospitalization: 35% reduction 1
- eGFR considerations: Can be initiated down to eGFR 20 mL/min/1.73 m² for heart failure indication 2
Dapagliflozin (Farxiga) 10 mg
- Single dose: Only one approved dose (10 mg) regardless of indication 3
- Broader eGFR range: Can be initiated down to eGFR 25 mL/min/1.73 m² and continued to eGFR 20 mL/min/1.73 m² 3
- Kidney outcomes: Proven benefit in DAPA-CKD trial for kidney disease progression
Pharmacodynamic Considerations
Research shows canagliflozin 300 mg produces approximately 25% higher 24-hour urinary glucose excretion (51.4 g vs 40.8 g) compared to dapagliflozin 10 mg 4. However, this pharmacodynamic difference does not translate to clinically meaningful differences in hard outcomes 5, 6.
A head-to-head comparison found empagliflozin and dapagliflozin had comparable long-term kidney outcomes in type 2 diabetes, with similar 6-year risks for acute kidney injury, chronic kidney disease progression, and albuminuria 6.
Clinical Decision Algorithm
With normal eGFR, choose based on:
If cardiovascular disease is present: Empagliflozin 25 mg has the strongest mortality benefit (32% reduction in all-cause mortality) 1
If heart failure is the primary concern: Either agent at maximum dose; both reduce HF hospitalization by approximately 33-35% 1
If chronic kidney disease is present or anticipated: Dapagliflozin 10 mg offers broader eGFR range for continuation as kidney function declines 3
For pure glycemic control: Either maximum dose is appropriate, though empagliflozin 25 mg may offer slightly more glucose lowering than the 10 mg dose 2
Important Caveats
- Both agents require the same monitoring: Volume status, genital mycotic infections, ketoacidosis risk 3
- No dose titration needed: Start at the target dose immediately 3, 2
- Insurance formularies: Often the deciding factor; both are clinically equivalent for most outcomes 6
- The 2022 ADA/KDIGO guidelines recommend SGLT2 inhibitors with proven kidney or cardiovascular benefit for patients with eGFR ≥20 mL/min/1.73 m² 3